Penumbra, Inc. (PEN)

NYQ – Real vaqt narxi. Valyuta: USD

322.79

+1.08 (0.34%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

Artisan Small Cap Fund Q1 2026 Portfolio Activity

During the quarter, we initiated new Garden positions in Onto Innovation, Baldwin Group and Freshpet. In addition to Compass, we added to our positions in Ollie's Bargain Outlet and Flowserve during the quarter. We ended our investment campaigns in Penumbra, JBT Marel and Parsons during the quarter.

06.05.2026

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra (PEN) came out with quarterly earnings of $0.82 per share, missing the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $0.83 per share a year ago.

06.05.2026

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

05.05.2026

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

27.04.2026

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

27.04.2026

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

15.04.2026

Here's Why Penumbra (PEN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

13.04.2026

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone.

08.04.2026

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Scientific common stock, subject to proration, for each share of Penumbra that they own. KSF is seeki.

25.02.2026

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.

Penumbra, Inc. (PEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Penumbra, Inc. (PEN)

Artisan Small Cap Fund Q1 2026 Portfolio Activity

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Here's Why Penumbra (PEN) is a Strong Growth Stock

Videolar

No Data

Press-relizlar

Penumbra, Inc. Reports First Quarter 2026 Financial Results

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Artisan Small Cap Fund Q1 2026 Portfolio Activity

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Here's Why Penumbra (PEN) is a Strong Growth Stock

Videolar

No Data

Press-relizlar

Penumbra, Inc. Reports First Quarter 2026 Financial Results

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Search stocks

Penumbra, Inc. (PEN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Penumbra, Inc. (PEN)

Artisan Small Cap Fund Q1 2026 Portfolio Activity

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Here's Why Penumbra (PEN) is a Strong Growth Stock

Videolar

No Data

Press-relizlar

Penumbra, Inc. Reports First Quarter 2026 Financial Results

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Artisan Small Cap Fund Q1 2026 Portfolio Activity

Penumbra (PEN) Misses Q1 Earnings Estimates

Penumbra, Inc. Reports First Quarter 2026 Financial Results

ALC vs. PEN: Which Stock Should Value Investors Buy Now?

3 Reasons Why Penumbra (PEN) Is a Great Growth Stock

Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts

Here's Why Penumbra (PEN) is a Strong Growth Stock

Videolar

No Data

Press-relizlar

Penumbra, Inc. Reports First Quarter 2026 Financial Results

New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients

Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results